Isomorphic Labs, the company that designs new medicines with artificial intelligence, has raised $5 billion in a Series C round. The company announced the investment on Tuesday, 17 November. The round was co-led by Greenoaks and Sequoia Capital, and Alphabet, an existing backer, put in more money again.
The round
Besides the two co-leads, the company names one new backer, Andreessen Horowitz (a16z), and says several other new investors joined without listing them. Every existing investor took part as well:
- Alphabet, described as making a continued significant investment
- Thrive Capital
- MGX
- GV
- CapitalG
- Temasek
- The UK Sovereign AI Fund
Isomorphic Labs did not give a valuation in its announcement.
What the company does
Isomorphic Labs uses AI to design and develop drug candidates. At the centre of its work is its own drug design engine, which it calls IsoDDE, together with a pipeline of potential treatments that were designed with the help of that engine. The company says it works on programmes across several disease areas and different types of medicine, and that its aim is to bring new treatments to patients around the world faster.
What the money is for
The announcement says the money will speed up the company's scientific work and its in-house AI research. The page also says Isomorphic is scaling both IsoDDE and its pipeline of AI-designed drug candidates. The company did not break down how the $5 billion will be spent, and it gave no figures for staff, the number of programmes or the timing of clinical trials. A fuller press release is linked from the announcement.
Background
This is the third outside round for the company in under two years, and each has been far larger than the last:
| Date | Round | Amount | Led by |
|---|---|---|---|
| 31 March 2025 | First external round | $600 million | Thrive Capital |
| 12 May 2026 | Series B | $2.1 billion | Thrive Capital |
| 17 November 2026 | Series C | $5 billion | Greenoaks and Sequoia Capital |
Added together, the three announced rounds come to $7.7 billion. In the first round, in March 2025, Thrive Capital was joined by GV, with follow-on money from Alphabet, which was already an investor. At that time the company said the money would go into its next-generation drug design engine and into moving its programmes into the clinic. The Series B in May brought in MGX, Temasek, CapitalG and the UK Sovereign AI Fund as new investors, and was meant to grow the engine, expand the business worldwide and move its drug candidates forward.
For more funding news, see AI Pulse.
Announced by Isomorphic Labs on its website: read the announcement







